• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC).

作者信息

Aieta Michele, Facchinetti Antonella, De Faveri Stefania, Manicone Mariangela, Tartarone Alfredo, Possidente Luciana, Lerose Rosa, Mambella Giuseppina, Calderone Giuseppe, Zamarchi Rita, Rossi Elisabetta

机构信息

Department of Onco-Hematology, Division of Medical Oncology, Centro di Riferimento Oncologico della Basilicata, IRCCS, Rionero in Vulture (PZ), Italy.

Department of Surgery, Oncology and Gastroenterology, Oncology Section, University of Padova, Padova, Italy; IOV-IRCCS, Padova, Italy.

出版信息

Clin Lung Cancer. 2016 Sep;17(5):e173-e177. doi: 10.1016/j.cllc.2016.05.002. Epub 2016 May 18.

DOI:10.1016/j.cllc.2016.05.002
PMID:27397482
Abstract
摘要

相似文献

1
Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC).EML4-ALK阳性非小细胞肺癌（NSCLC）患者循环肿瘤细胞（CTC）的监测与特征分析
Clin Lung Cancer. 2016 Sep;17(5):e173-e177. doi: 10.1016/j.cllc.2016.05.002. Epub 2016 May 18.
2
Expanded Circulating Tumor Cells from a Patient with ALK-Positive Lung Cancer Present with EML4-ALK Rearrangement Along with Resistance Mutation and Enable Drug Sensitivity Testing: A Case Study.一名ALK阳性肺癌患者的循环肿瘤细胞扩增，呈现EML4-ALK重排并伴有耐药突变，可用于药物敏感性测试：一项病例研究。
J Thorac Oncol. 2017 Feb;12(2):397-402. doi: 10.1016/j.jtho.2016.07.027. Epub 2016 Aug 6.
3
Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.靶向干性是控制EML4-ALK+非小细胞肺癌细胞的有效策略。
Oncotarget. 2015 Nov 24;6(37):40255-67. doi: 10.18632/oncotarget.5434.
4
Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.重排的EML4-ALK融合转录本在循环血血小板中隔离，并能够在非小细胞肺癌中进行基于血液的克唑替尼反应监测。
Oncotarget. 2016 Jan 5;7(1):1066-75. doi: 10.18632/oncotarget.6279.
5
Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.EML4-ALK 融合检测及一线克唑替尼治疗对晚期 ALK 阳性非小细胞肺癌患者的成本效果分析。
J Clin Oncol. 2014 Apr 1;32(10):1012-9. doi: 10.1200/JCO.2013.53.1186. Epub 2014 Feb 24.
6
Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.克唑替尼诱发的急性间质性肺病，发生在一名EML4-ALK阳性非小细胞肺癌合并慢性间质性肺炎的患者身上。
Acta Oncol. 2014 Jan;53(1):158-60. doi: 10.3109/0284186X.2013.802838. Epub 2013 Jun 11.
7
Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without prior exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy?ALK G1202R溶剂前沿突变与小细胞肺癌转化双重出现作为对第二代ALK抑制剂的耐药机制，且未预先接触过克唑替尼。仅依靠液体再活检的陷阱？
Lung Cancer. 2017 Apr;106:110-114. doi: 10.1016/j.lungcan.2017.02.005. Epub 2017 Feb 9.
8
Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.在对阿来替尼耐药的两个存在 ALK 重排的非小细胞肺癌（NSCLC）患者中发现了一种新型的 HIP1-ALK 融合变体和 ALK I1171（I1171N/S）突变。
J Thorac Oncol. 2014 Dec;9(12):1821-5. doi: 10.1097/JTO.0000000000000368.
9
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.EML4-ALK 阳性非小细胞肺癌中 HER 家族信号激活作为获得性对 ALK 抑制剂耐药的机制。
Clin Cancer Res. 2012 Nov 15;18(22):6219-26. doi: 10.1158/1078-0432.CCR-12-0392. Epub 2012 Jul 27.
10
[Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].[具有转化型EML4-ALK融合基因的患者对克唑替尼耐药的机制]
Zhonghua Bing Li Xue Za Zhi. 2012 Dec;41(12):862-4. doi: 10.3760/cma.j.issn.0529-5807.2012.12.020.

引用本文的文献

1
Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer.液体活检分析在非小细胞肺癌 TKI 治疗中的应用。
Cells. 2022 Sep 14;11(18):2871. doi: 10.3390/cells11182871.
2
New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)-Positive Cancer.间变性淋巴瘤激酶（ALK）阳性癌症液体活检技术的新进展
Cancers (Basel). 2021 Oct 14;13(20):5149. doi: 10.3390/cancers13205149.
3
Progress and application of circulating tumor cells in non-small cell lung cancer.循环肿瘤细胞在非小细胞肺癌中的研究进展与应用
Mol Ther Oncolytics. 2021 May 19;22:72-84. doi: 10.1016/j.omto.2021.05.005. eCollection 2021 Sep 24.
4
Case Report: Circulating Tumor Cells as a Response Biomarker in ALK-Positive Metastatic Inflammatory Myofibroblastic Tumor.病例报告：循环肿瘤细胞作为ALK阳性转移性炎性肌纤维母细胞瘤的反应生物标志物
Front Pediatr. 2021 Apr 29;9:652583. doi: 10.3389/fped.2021.652583. eCollection 2021.
5
Molecular diagnosis in non-small-cell lung cancer: expert opinion on and testing.非小细胞肺癌的分子诊断：专家意见与 和 检测。
J Clin Pathol. 2022 Mar;75(3):145-153. doi: 10.1136/jclinpath-2021-207490. Epub 2021 Apr 19.
6
A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients.一种用于检测循环肿瘤细胞（CTC）中泛细胞角蛋白和EML4-ALK融合蛋白表达的全自动检测方法可预测非小细胞肺癌（NSCLC）患者的预后。
Transl Lung Cancer Res. 2021 Jan;10(1):80-92. doi: 10.21037/tlcr-20-855.
7
Detection of Circulating Tumor Cells in the Diagnostic Leukapheresis Product of Non-Small-Cell Lung Cancer Patients Comparing CellSearch and ISET.比较CellSearch和ISET检测非小细胞肺癌患者诊断性白细胞分离术产品中的循环肿瘤细胞
Cancers (Basel). 2020 Apr 7;12(4):896. doi: 10.3390/cancers12040896.
8
The Role of Circulating Tumor Cells in the Metastatic Cascade: Biology, Technical Challenges, and Clinical Relevance.循环肿瘤细胞在转移级联反应中的作用：生物学、技术挑战及临床相关性
Cancers (Basel). 2020 Apr 3;12(4):867. doi: 10.3390/cancers12040867.
9
The combination of CTCs and CEA can help guide the management of patients with SPNs suspected of being lung cancer.循环肿瘤细胞（CTC）与癌胚抗原（CEA）联合检测有助于指导肺部孤立性结节（SPN）疑似肺癌患者的管理。
BMC Cancer. 2020 Feb 10;20(1):106. doi: 10.1186/s12885-020-6524-1.
10
The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer.循环肿瘤细胞（CTCs）在肺癌中的预后作用
Front Oncol. 2018 Aug 14;8:311. doi: 10.3389/fonc.2018.00311. eCollection 2018.